Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Cymraeg
Cymraeg
Search
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
22/05/2020
TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
18/05/2020
TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
18/05/2020
TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
18/05/2020
TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
18/05/2020
TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
18/05/2020
TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
18/05/2020
TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
18/05/2020
TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
18/05/2020
TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
18/05/2020
TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
15/05/2020
TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
13/05/2020
TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
13/05/2020
TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
13/05/2020
TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
13/05/2020
TA434: Elotuzumab for previously treated multiple myeloma (terminated appraisal)
13/05/2020
TA408: Pegaspargase for treating acute lymphoblastic leukaemia
13/05/2020
TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
13/05/2020
TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
13/05/2020
TA506: Lesinurad for treating chronic hyperuricaemia in people with gout
05/05/2020
TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
8
9
10
11
12
13
14
15
16
17
18
Follow AWTTC: